Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04580589
Other study ID # C02-001 SC003
Secondary ID
Status Completed
Phase
First received
Last updated
Start date February 1, 2021
Est. completion date October 31, 2022

Study information

Verified date February 2023
Source Cipherome, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to see if the participant's genetic profile and clinical factors (age, drug dose, etc.) affect drug outcomes (i.e. serious bleeding) that the participant may have experienced since taking the drug (direct oral anticoagulant) for preventing blood clots from forming in the blood vessels.


Description:

Genes can have variants or mutations that can increase the participant's risk for bleeding when receiving a direct oral anticoagulant (DOACs). The investigators will be studying participants on DOACs who have had bleeding and also participants who are on DOACs who did not have bleeding (control group). The goal of the study is to determine the accuracy of Cipherome's Drug Safety Score (DSS) in it's ability to predict adverse drug reactions (ADRs). A DSS score ranges from 0 to 1, with scores less than 0.3 correlated with a higher risk of ADRs and scores more than 0.7 correlated with a lower risk of ADRs. The participant's DSS score will be compared with the actual clinical outcome using a statistical test to determine the accuracy of the DSS.


Recruitment information / eligibility

Status Completed
Enrollment 210
Est. completion date October 31, 2022
Est. primary completion date October 31, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria: - Any adult patient 18 years and older, who experienced major bleeding, clinically relevant non major bleeding or treatment failure while taking a DOAC during the study time frame and is able to provide informed consent. Control patients will be recruited from all adult patients who are on DOAC therapy. Exclusion Criteria: - Failure to provide informed consent

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States Santa Clara Valley Medical Center Santa Clara California

Sponsors (2)

Lead Sponsor Collaborator
Cipherome, Inc. Santa Clara Valley Medical Center

Country where clinical trial is conducted

United States, 

References & Publications (15)

1000 Genomes Project Consortium; Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, Marchini JL, McCarthy S, McVean GA, Abecasis GR. A global reference for human genetic variation. Nature. 2015 Oct 1;526(7571):68-74. doi: 10.1038/nature15393. — View Citation

Bauer KA. Pros and cons of new oral anticoagulants. Hematology Am Soc Hematol Educ Program. 2013;2013:464-70. doi: 10.1182/asheducation-2013.1.464. — View Citation

Beckman MG, Hooper WC, Critchley SE, Ortel TL. Venous thromboembolism: a public health concern. Am J Prev Med. 2010 Apr;38(4 Suppl):S495-501. doi: 10.1016/j.amepre.2009.12.017. — View Citation

Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013 Oct 15;112(8):1142-7. doi: 10.1016/j.amjcard.2013.05.063. Epub 2013 Jul 4. — View Citation

Dimatteo C, D'Andrea G, Vecchione G, Paoletti O, Cappucci F, Tiscia GL, Buono M, Grandone E, Testa S, Margaglione M. Pharmacogenetics of dabigatran etexilate interindividual variability. Thromb Res. 2016 Aug;144:1-5. doi: 10.1016/j.thromres.2016.05.025. Epub 2016 May 26. — View Citation

Ing Lorenzini K, Daali Y, Fontana P, Desmeules J, Samer C. Rivaroxaban-Induced Hemorrhage Associated with ABCB1 Genetic Defect. Front Pharmacol. 2016 Dec 19;7:494. doi: 10.3389/fphar.2016.00494. eCollection 2016. — View Citation

Kanuri SH, Kreutz RP. Pharmacogenomics of Novel Direct Oral Anticoagulants: Newly Identified Genes and Genetic Variants. J Pers Med. 2019 Jan 17;9(1):7. doi: 10.3390/jpm9010007. — View Citation

Kirley K, Qato DM, Kornfield R, Stafford RS, Alexander GC. National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes. 2012 Sep 1;5(5):615-21. doi: 10.1161/CIRCOUTCOMES.112.967299. Epub 2012 Sep 4. — View Citation

Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, Kvamme AM, Friedman J, Mismetti P, Goldhaber SZ; RE-MEDY Trial Investigators; RE-SONATE Trial Investigators. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013 Feb 21;368(8):709-18. doi: 10.1056/NEJMoa1113697. — View Citation

Sennesael AL, Larock AS, Douxfils J, Elens L, Stillemans G, Wiesen M, Taubert M, Dogne JM, Spinewine A, Mullier F. Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study. Thromb J. 2018 Nov 12;16:28. doi: 10.1186/s12959-018-0183-3. eCollection 2018. — View Citation

Shi J, Wang X, Nguyen JH, Bleske BE, Liang Y, Liu L, Zhu HJ. Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender. Biochem Pharmacol. 2016 Nov 1;119:76-84. doi: 10.1016/j.bcp.2016.09.003. Epub 2016 Sep 8. — View Citation

Sychev DA, Levanov AN, Shelekhova TV, Bochkov PO, Denisenko NP, Ryzhikova KA, Mirzaev KB, Grishina EA, Gavrilov MA, Ramenskaya GV, Kozlov AV, Bogoslovsky T. The impact of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty. Pharmgenomics Pers Med. 2018 Jul 25;11:127-137. doi: 10.2147/PGPM.S169277. eCollection 2018. Erratum In: Pharmgenomics Pers Med. 2018 Sep 26;11:167. — View Citation

Ueshima S, Hira D, Kimura Y, Fujii R, Tomitsuka C, Yamane T, Tabuchi Y, Ozawa T, Itoh H, Ohno S, Horie M, Terada T, Katsura T. Population pharmacokinetics and pharmacogenomics of apixaban in Japanese adult patients with atrial fibrillation. Br J Clin Pharmacol. 2018 Jun;84(6):1301-1312. doi: 10.1111/bcp.13561. Epub 2018 Apr 16. — View Citation

Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med. 2007 Jul 9;167(13):1414-9. doi: 10.1001/archinte.167.13.1414. — View Citation

Zareh M, Davis A, Henderson S. Reversal of warfarin-induced hemorrhage in the emergency department. West J Emerg Med. 2011 Nov;12(4):386-92. doi: 10.5811/westjem.2011.3.2051. — View Citation

* Note: There are 15 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Other Discovery of novel genetic variants To discover novel pharmacogenomic variants associated with DOAC metabolism. The investigators will be conducting whole genome sequencing to determine novel variants found in individuals with major bleeding or treatment failures. Within 1 year of DOAC therapy initiation
Primary Major bleeding event during DOAC therapy Reduction in hemoglobin of at least 2 g/dL
Blood loss requiring transfusion of at least 2 units of whole blood or erythrocytes
Critical anatomical sites of bleeding: intramuscular with compartment syndrome, intracranial, intraspinal, retroperitoneal, intraocular, pericardial, and atraumatic intra-articular bleeding.
Bleeding leading to death
Within 1 year of DOAC therapy initiation
Primary Clinically relevant non-major bleeding Hospital admission for bleeding, or
Physician guided medical or surgical treatment for bleeding, or
Change in antithrombotic therapy (including interruption or discontinuation of study drug).
Within 1 year of DOAC therapy initiation
Secondary Thromboembolic events Thromboembolic events including, but not limited to: deep vein thrombosis, pulmonary embolism, ischemic stroke, transient ischemic attack, arterial thrombosis, or other thromboembolic event Within 1 year of DOAC therapy initiation
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03258151 - Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
Recruiting NCT05202964 - Compliance and Tolerance to Oral AntiBiotherapy in Osteoarticular Infections (OTABIO)
Completed NCT04597593 - Association Between Genetic Variant Scores and DOACs (DARES2)
Recruiting NCT05096338 - Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Prostate Cancer
Recruiting NCT05078190 - Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Breast Cancer
Completed NCT02457039 - Acupuncture Prevents Chemobrain in Breast Cancer Patients N/A
Completed NCT02779530 - CYP4A11 and CYP4F2 Gene Variants as Makers of Cardiovascular Adverse Events of Non-steroidal Anti-inflammatory Drugs Phase 4
Recruiting NCT03051880 - Preventive Effect of EGF Cream for Cutaneous Adverse Event of EGFR Inhibitors N/A
Recruiting NCT03047863 - Therapeutic Effect of EGF Cream for Cutaneous Adverse Event of EGFR Inhibitors N/A
Completed NCT02482025 - The Secure Messaging for Medication Reconciliation Tool (SMMRT) Trial N/A
Not yet recruiting NCT03147157 - The Effect of Human Leukocyte Antigen Macthing on Guiding Tacrolimus Regimen After Liver Transplantation N/A
Recruiting NCT03156348 - Impact of Clinical Pharmacist on Adverse Drug Events in Older Adults N/A
Recruiting NCT03501108 - Discontinuation of Long-term Medications in Older People Entering Nursing Home Care N/A
Recruiting NCT06427317 - Routinely Collected Clinical Data and Evaluation of Antimicrobial Target Attainment
Completed NCT03227653 - Neuropsychiatric Side Effects of Efavirenz in Children Living With HIV
Completed NCT03177174 - Different Chemotherapy Protocols Combined With Intensity Modulated Radiation Therapy in Patients With Locally Advanced Nasopharyngeal Carcinoma N/A
Recruiting NCT04077281 - Improving Medication Prescribing-Related Outcomes for Vulnerable Elderly In Transitions N/A
Not yet recruiting NCT05247814 - Individual Risk Profiles for Adverse Drug Reactions in Geriatric Patients
Recruiting NCT03938597 - Investigation of Serious Adverse Events Following Vaccination Against Yellow Fever: Emphasis on Genetic Basis and Biological Markers
Recruiting NCT06291688 - Applying Mobile Healthcare Education to Improve Cutaneous Self-care Capability N/A